Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYalçın, Serap
dc.contributor.authorYalçınkaya, Seda
dc.contributor.authorErcan, Fahriye
dc.date.accessioned2025-02-18T11:31:16Z
dc.date.available2025-02-18T11:31:16Z
dc.date.issued2021en_US
dc.identifier.citationYalçın, S., Yalçınkaya, S., & Ercan, F. (2021). Determination of potential drug candidate molecules of the Hypericum perforatum for COVID-19 treatment. Current pharmacology reports, 7, 42-48.en_US
dc.identifier.issn2198641X
dc.identifier.urihttps://10.1007/s40495-021-00254-9
dc.identifier.urihttps://hdl.handle.net/20.500.12513/7103
dc.description.abstractThe novel human coronavirus was firstly emerged in December 2019 in Wuhan, China, and has spread rapidly around the world. There is no known specific effective treatment of COVID-19. The most commonly used agents against this disease both in Turkey and around the world include chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir, and remdesivir. In the study, we investigated the drug potential of molecules that the components of an important medicinal plant Hypericum perforatum by using molecular docking and drug possibility properties of these molecules. The molecular docking results showed that the most stable complex was obtained with COVID-19 main protease and hypericin/isohypericin ligands with − 11 kcal/mol binding energy. Furthermore, ADMET, drug-likeness features of compounds of H. perforatum were investigated using the rules of Lipinski, Veber, and Ghose. According to the results obtained, it has been shown that H. perforatum has the potential to be an effective drug in the COVID-19 pandemic. In the next stage, it is necessary to carry out the clinically necessary reliability studies of these components. It is thought that it can be used for the treatment of COVID-19 if our molecular docking results are found to be in high correlation with clinical studies. © 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature.en_US
dc.language.isoengen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.relation.isversionof10.1007/s40495-021-00254-9en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectADMETen_US
dc.subjectCOVID-19en_US
dc.subjectDrug-likeness Drugen_US
dc.subjectHypericum Perforatumen_US
dc.subjectMolecular Dockingen_US
dc.titleDetermination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatmenten_US
dc.typeotheren_US
dc.relation.journalCurrent Pharmacology Reportsen_US
dc.contributor.departmentFen Edebiyat Fakültesien_US
dc.contributor.authorIDSerap Yalçın Azarkan / 0000-0002-9584-266Xen_US
dc.contributor.authorIDFahriye Ercan / 0000-0002-0111-8460en_US
dc.identifier.volume7en_US
dc.identifier.issue2en_US
dc.identifier.startpage42en_US
dc.identifier.endpage48en_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster